

**FORM 51-102F3
MATERIAL CHANGE REPORT
UNDER NATIONAL INSTRUMENT 51-102**

Item 1 Name and Address of Company

Abattis Bioceuticals Corp. (the "Issuer")
104 - 9295 198th Street,
Langley, B.C., V1M 3J9

Item 2 Date of Material Change

November 14, 2016

Item 3 News Release

A news release was disseminated on November 14, 2016 through the facilities of NewsFile and subsequently filed on SEDAR.

Item 4 Summary of Material Change

On November 14, 2016 Abattis Bioceuticals Corp. (the "**Company**" or "**Abattis**") (OTCQB: ATTBF) (CSE: ATT) announced the appointment of Dr. Shuang Xie to the Board of Directors. Dr. Xie recently joined Abattis as the Chief Technology Advisor and continues in that capacity. Abattis also provide an update on its initiatives in China.

Item 5 Full Description of Material Change

On November 14, 2016 Abattis announced the appointment of Dr. Shuang Xie to the Board of Directors. Dr. Xie recently joined Abattis as the Chief Technology Advisor and continues in that capacity. Abattis also provided an update on its initiatives in China.

Dr. Shuang Xie has been diligently working in China to increase the profile of Abattis Bioceuticals and working toward establishing exclusive venture partnerships.

Dr. Xie was instrumental in bringing the Green Nature deal to Abattis which will increase our profile in the food and nutraceutical industry in Canada, China, Taiwan, South East Asia and Japan. Green Nature is contracted to bring in revenues from existing sales channels in Asia. She is mandated to maintain revenue through existing channels and provide new revenue streams with our nutraceutical formulations.

For the past few months, Dr. Xie has been working toward commercializing the advanced proprietary technology for the extraction Cannabinol ("CBD") and Tetrahydrocannabinol ("THC"). She is establishing relationships to serve the advancement and completion of the extraction technology for commercial use in North America. It is expected that agreements for the use of the technology will be finalized in early 2017.

In concert with Abattis' efforts in Canada in our Langley testing lab and the potential for a Health Canada production license for Experion, this extraction technology will provide another layer of integration for Abattis. The Company is performing on its business plan to provide rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company's operating protocols, adhere to the applicable laws of Canada and foreign jurisdictions.

The Company also wishes to announce that it has issued 1,142,857 Common Shares to a consultant of the Company in satisfaction of sums owed. The shares were purchased under an exemption from prospectus requirements contained in s. 2.24 of NI 45-106 provided to employees, officers, directors and consultants of an Issuer.

Lastly, the Company announces that it has issued 485,434 common shares as compensation for services to consultants, directors and employees of the Company for the month ended October 31, 2016 and in respect of shares issued pursuant to the appointment for Dr. Panenka to the board of directors, no legend was required on any of the issued shares.

Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102

N/A

Item 7 Omitted Information

N/A

Item 8 Executive Officer

Rene David
CFO
Abattis Bioceuticals Corp.
Tel: 604.336.0881

Item 9 Date of Report

November 17, 2016

Cautionary Note Regarding Forward Looking Statements

This material change report contains certain forward-looking statements about the Company's future plans and intentions, including statements relating to the Company's intention to implement changes across its business to achieve growth. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "scheduled" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect Management's current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.